NSE: HESTERBIO | BSE: 524669 | ASM

Expensive Performer

Download real time

1645.60 -42.60 (-2.52%)

51.30% Fall from 52W High

30,204 NSE+BSE Volume

NSE 09 May, 2025 3:31 PM (IST)

1,399.9

Market Cap

Above industry Median

1.0

Beta 1Year

Average volatility

Rapid Results

Q4FY25 Quarterly Result Announced for Hester Biosciences Ltd. See details

Hester Biosciences Ltd. share price target and research reports

Name: Latest research reports of Hester Biosciences Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Hester Biosciences Ltd.
Rating: 5
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for HESTERBIO, BSE:524669 Hester Biosciences Ltd.

Hester Biosciences Ltd.

30 Oct 2018

1645.60

-2.52%

Hester Biosciences

Buy: Hester Biosciences Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Standalone revenues grew 20% YoY in H1FY19 to | 80.8 crore on the back of 36% growth in the large animal segment to | 14.8 crore and addition of veterinary social business. The poultry segment grew 10% YoY in H1FY19 to | 62.3 crore EBITDA margins remained healthy at 38% in H1FY19. EBITDA grew 18% YoY in H1FY19 to | 30.5 crore Net profit grew 30% YoY to | 19.6 in H1FY19 crore mainly due to a...

Hester Biosciences Ltd. is trading below its 30 day SMA of 1691.3

Hester Biosciences Ltd.

25 Jan 2018

1645.60

-2.52%

Hester Biosciences

Buy: Hester Biosciences Ltd.

Target

ICICI Securities Limited

Hester Biosciences Ltd. is trading above its 50 day SMA of 1595.1

Hester Biosciences Ltd.

30 Nov 2017

1645.60

-2.52%

Hester Biosciences Ltd: High-margin Large Animal Vaccines Sa... (Nov 30, 2017)

Buy: Hester Biosciences Ltd.

Target

Karvy

Domestic Brucella and PPR Vaccines Sales Drive Profitability: A surprise and significant jump in domestic Large Animal Vaccines (LAV) sales - primarily Brucella vaccine and to smaller degree PPR vaccines - have led to considerableexpansion in gross margin and EBITDA margin.

Hester Biosciences Ltd. is trading below its 30 day SMA of 1691.3

Hester Biosciences Ltd.

13 Nov 2017

1645.60

-2.52%

Hester Biosciences

Buy: Hester Biosciences Ltd.

Target

ICICI Securities Limited

Hester Biosciences Ltd. has lost -38.44% in the last 6 Months

Hester Biosciences Ltd.

29 Mar 2017

1645.60

-2.52%

Hester Biosciences

Buy: Hester Biosciences Ltd.

ICICI Securities Limited

Hester Biosciences Ltd. is trading above its 50 day SMA of 1595.1

Hester Biosciences Ltd.

20 Dec 2016

1645.60

-2.52%

Hester Biosciences Ltd: Results In-Line with Expectations; N... (Dec 20, 2016)

Buy: Hester Biosciences Ltd.

Target

Karvy

Nepal Plant Commissioned: The PPR vaccines manufacturing facility in Nepal has started commercial operations and would be manufacturing PPR vaccines for exports primarily to African countries. Commissioning of plant was delayed because of which most of PPR sales are likely to occur in the year 2017E and thereafter. We believe that successful operations of this plant are expected to lead to manufacturing of safe and effective vaccines, and thus is a defining moment in the history of HesterBiosciences Ltd (HBL). PPR is a plague affecting Sheep and Goats.

Hester Biosciences Ltd. is trading above its 50 day SMA of 1595.1

Hester Biosciences Ltd.

03 Aug 2016

1645.60

-2.52%

Hester Biosciences Ltd 1QFY17 result update

Hold: Hester Biosciences Ltd.

BOB Capital Markets Ltd.

Hester Biosciences Ltd. posted robust growth in 1QFY17 with revenue growth of 22.8%/6.9% YoY/QoQ, respectively, to Rs 301mn led by 21.6%/41% growth in poultry segment/Large animal segment. EBITDA for the quarter grew by 31%/9.8% YoY/QoQ respectively to Rs 107mn with the expansion in EBITDA margins by 222/94bps YoY/QoQ to 35.5% mainly due to shift in product mix, better inventory management, credit control and lower financing cost.

Hester Biosciences Ltd. is trading above its 50 day SMA of 1595.1

Hester Biosciences Ltd.

10 May 2016, 12:00AM

1645.60

-2.52%

Hester Biosciences Ltd 4QFY16 result Review

Hold: Hester Biosciences Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Steady performance captured in price; revised to Hold Hester Biosciences Ltd. posted robust growth in 4QFY16 with revenue growth of 21%/17% YoY/QoQ, respectively, to Rs 282mn led by 9%/96%...

Hester Biosciences Ltd. is trading above its 50 day SMA of 1595.1

Hester Biosciences Ltd.

21 Mar 2016

1645.60

-2.52%

Hester Biosciences ltd Initiating coverage with BUY

Buy: Hester Biosciences Ltd.

BOB Capital Markets Ltd.

Poultry vaccines to grow at ~16%: Poultry segment in India commands 2nd most important place after Livestock. India is third largest country in Egg production with 70 billion eggs and at fourth largest in broiler / chicken meat...